The growing complexity and variability in healthcare delivery and costs within Medicare Advantage (MA) and Medicare Supplement (Medigap) plans present significant challenges for improving health outcomes and managing expenditures. Neural networks, a subset of artificial intelligence (AI), have shown considerable promise in optimizing healthcare processes, particularly in predictive modeling, personalized treatment recommendations, and risk stratification. This paper explores the application of neural networks in enhancing health outcomes within the context of Medicare Advantage and Supplement plans. We review how deep learning models can be leveraged to predict patient risk, optimize resource allocation, and identify at-risk populations for preventive interventions. Additionally, we discuss the potential for neural networks to improve claims processing, reduce fraud, and streamline administrative burdens. By integrating various data sources, including medical records, claims data, and demographic information, neural networks enable more accurate and efficient decision-making processes. Ultimately, this approach can lead to better patient care, reduced healthcare costs, and improved satisfaction for beneficiaries of these programs. The paper concludes by highlighting the current limitations, ethical considerations, and future directions for AI adoption in the Medicare Advantage and Supplement sectors.

Advances in web-centric cloud computing have facilitated the establishment of an integrated cloud environment connecting a wide variety of clinical trial stakeholders. A web-centric cloud framework is proposed for real-time monitoring and risk prediction during clinical trials. The framework focuses on identifying relevant datasets, developing a data-management interface, and implementing machine-learning algorithms for data analysis. Detailed descriptions of the data-management interface and the machine-learning processes are provided, targeting active clinical trials with therapeutic uses in cancer. Demonstrations utilize publicly available clinical-trial data from the ClinicalTrials.gov repository. The real-time monitoring and risk prediction systems were assessed by developing five supervised-classification-machine-learning models for trial-status prediction and six unsupervised models for patient-safety-profile assessment, each representing a different phase of the clinical-trial process. All supervised models yielded high accuracy and area-under-the-curve values at the testing stage, while the unsupervised models demonstrated practical applicability. The results underscore the advantages of using the trial-status algorithm, the patient-safety-profile model, and the proposed framework for performing real-time monitoring and risk prediction of clinical trials.